Si Hyen Cho


Affiliation: Fraunhofer Institute of Toxicology and Experimental Medicine
Country: Germany


  1. Borlak J, Gasparic A, Locher M, Schupke H, Hermann R. N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006;55:711-21 pubmed
    ..We therefore suggest N-glucuronidation of retigabine to be of importance in the metabolic clearance of this drug. ..
  2. Borlak J, Reamon Buettner S. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet. 2006;7:58 pubmed
    ..Our study failed to show an overall association of NAT2 genotypes to either colon or lung cancer risk. ..
  3. Borlak J, Thum T. Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J. 2003;17:1592-608 pubmed
    ..Overall, the reversal of repressed ion channel gene expression in patients with implanted assist devices exemplifies the complex interactions between pressure load/stretch force and heart-specific gene expression. ..
  4. Borlak J, Meier T, Halter R, Spanel R, Spanel Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene. 2005;24:1809-19 pubmed
    ..Our study provided new information on the tumour stage-dependent network of EGF-regulated genes, and we identified candidate genes linked to tumorigenes and progression of disease. ..
  5. Reymann S, Borlak J. Topoisomerase II inhibition involves characteristic chromosomal expression patterns. BMC Genomics. 2008;9:324 pubmed publisher
    ..They did, however, not always show similar expression levels, and many of the regulated genes were, in fact, repressed...
  6. Borlak J, Klutcka T. Expression of basolateral and canalicular transporters in rat liver and cultures of primary hepatocytes. Xenobiotica. 2004;34:935-47 pubmed
    ..The findings point to a dramatic change in the expression of basolateral and canalicular transporters in cultured hepatocytes, and this should be considered when hepatocytes are used for drug profiling studies...
  7. Borlak J, Reamon Buettner S. N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease. BMC Med Genet. 2006;7:30 pubmed
    ..Results of the meta-analyses did not also provide conclusive evidence for an overall association of NAT2 slow acetylator genotypes to PD. ..
  8. Borlak J, Jenke H. Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation. Mol Cancer Res. 2008;6:1326-36 pubmed publisher
    ..Taken collectively, we show AhR to be a master regulator of c-raf and propose cross-talk between AhR and the mitogen-activated protein kinase signaling pathway in chemically induced hepatocarcinogenesis. ..
  9. Borlak J, Niehof M. HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. PLoS ONE. 2009;4:e4662 pubmed publisher
    ..We propose cyclosporine to repress HNF4alpha gene and protein expression, DNA-binding to targeted promoters and subsequent regulation of genes coding for glucose metabolism and of pancreatic beta-cell function. ..

More Information


  1. Borlak J, Zwadlo C. Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. Xenobiotica. 2003;33:927-43 pubmed
    ..5. Overall, CYP gene expression correlated well with the cognate enzyme activity using testosterone as a marker substrate...